WuXi Biologics (Cayman) Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a WXXWY research report →
About the company
WuXi Biologics (Cayman) Inc. delivers integrated solutions covering the entire lifecycle of biological drug development, from initial discovery to full-scale manufacturing. These services are provided to clients worldwide, with a significant presence in China, North America, and Europe.
- CEO
- Zhisheng Chen
- IPO
- 2017
- Employees
- 12,575
- HQ
- Wuxi, CN
Price Chart
- Market Cap
- $18.60B
- P/E
- 27.88
- P/S
- 6.17
- P/B
- 2.90
- EV/EBITDA
- 16.19
- Div Yield
- 0.00%
- Gross Margin
- 45.98%
- Op Margin
- 30.47%
- Net Margin
- 22.53%
- ROE
- 10.64%
- ROIC
- 9.26%
- Revenue
- $21.20B · 13.50%
- Net Income
- $4.77B · 42.27%
- EPS
- $2.38 · 52.56%
- Op Income
- $6.47B
- FCF YoY
- 117.05%
- 52W High
- $11.21
- 52W Low
- $6.20
- 50D MA
- $8.36
- 200D MA
- $9.02
- Beta
- 0.58
- Avg Volume
- 79.90K
Get TickerSpark's AI analysis on WXXWY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our WXXWY coverage
Recent articles, reports, and earnings notes.
No research on WXXWY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate WXXWY report →Similar companies
Peers in the same neighborhood.